Stephan J Pandol, MD, Professor of
Medicine, Cedars-Sinai Medical Center (Los Angeles, CA) serves as Armida Labs
Chief Medical Officer. Pandol has over 30 years of clinical research experience
focused on mechanisms of physiology and pathophysiology of the gastrointestinal
tract with an emphasis on exocrine pancreatic disorders. His work on pancreatic
cancer is focused on mechanisms of metastasis and resistance to therapy. He
found that circulating tumor cells are resistant to current therapies hence the agents
being developed at Armida Labs are highly relevant to developing novel effective
therapeutics against pancreatic cancer and other solid tumors. The Pandol
Laboratory at the Cedars-Sinai Pancreatic Research Program is dedicated to
establishing and maintaining the leading international research area at
Cedars-Sinai for advancing the prevention, early diagnosis, and treatment of
pancreatic diseases. Basic and translational research efforts at the Pancreatic
Research Program are designed to advance the clinical care of cancer patients. The
Pandol Laboratory is affiliated with the Pancreatic and Biliary Diseases
Program and the Samuel Oschin Comprehensive Cancer Institute.
Andrew E Hendifar is an oncologist in
Los Angeles, California, and is affiliated with multiple hospitals in the area,
including Keck Medical Center of USC and Cedars-Sinai Medical Center. He
received his medical degree from Tulane University School of Medicine and has
been in practice for more than 20 years. Andrew E Hendifar has expertise in
treating small intestine/colorectal cancer and prostate cancer, among other
conditions—see all areas of expertise. Hendifar accepts Medicare, Blue Cross,
and United Healthcare—see other insurance plans accepted.
Neil A Bhowmick, Ph.D., Professor of
Medicine at Cedars-Sinai Medical Center. He is the Director of the Cancer
Biology Program at Cedars-Sinai Cancer (ranked 7th by US News & World
Report), serves on the editorial boards of four scientific journals, is a charter
member of an NIH grant study section, and serves as the Chief Scientific Officer
for Armida Labs, Inc. Bhowmick brings more than 20 years of broad biochemistry
and cancer biology expertise; he has published in peer-reviewed journals on topics
ranging from pre-clinical cancer studies to translational research, including
regulatory approvals and clinical trials. Bhowmick is credited for
defining the role of fibroblasts in cancer initiation as an alternative
mechanism to the familiar two-hit hypothesis where one epigenetic alteration is
in the fibroblasts, complementing a mutation in the epithelia. He has gone on
to discover the role of fibroblasts in cancer therapy resistance and has used
these findings to extend the time of cancer remission in multiple cancer types
in preclinical and clinical studies. Bhowmick was also among the first to show
the tumor-suppressive role of fibroblasts and their role in collagen matrix
assembly in supporting the strength of healed skin wounds. He was a founder and
CEO of Enviro Therapeutics Inc., recently acquired and taken public. He trained
at Vanderbilt University.
Jun Gong specializes in hematology oncology in West Hollywood, CA, and has over 12 years of experience in the field of medicine. He graduated from New York Medical College with his medical degree in 2012. He is affiliated with numerous hospitals in California, including Cedars-Sinai Medical Center. Jun Gong is licensed to practice by the state board in California (A129164). Gong also practices at 8700 Beverly Boulevard, West Hollywood, CA. He is accepting new patients at his medical office, and is available for appointments, preventative care, medical care, as well as ongoing patient care.
